The CNSide® Diagnostics team is excited to announce our participation in the 2026 SNO/ASCO CNS Cancer Conference in Boston, where we will showcase the latest advancements in cerebrospinal fluid (CSF)-based diagnostics for patients & physicians with leptomeningeal metastases (LM).
As the clinical community continues to seek earlier, more accurate methods to diagnose and monitor CNS disease, we look forward to connecting with neuro-oncology, medical oncology, pathology, and laboratory professionals to discuss how CNSide is helping transform the management of patients with LM.
Visit Our Booth
Stop by our exhibit to learn more about the complete CNSide Diagnostics portfolio and how our proprietary platform is supporting clinicians with actionable insights from cerebrospinal fluid.
Our team will be available to discuss:
- CNSide® Tumor Cell Enumeration (TCE) for the detection and quantification of tumor cells in CSF
- Advanced CSF testing capabilities, including Immunocytochemistry (ICC), FISH, and Next-Generation Sequencing (NGS)
- Clinical evidence supporting improved diagnostic sensitivity compared with conventional CSF cytology
- How CNSide testing can support diagnosis, treatment monitoring, and clinical decision-making for patients with leptomeningeal metastases
Whether you are already using CNSide or are interested in incorporating advanced CSF diagnostics into your practice as a physician or oncologist, we'd welcome the opportunity to meet with you.
Note: CNSide will be showcased at our parent company’s booth: Cerenome (formally known as Plus Therapeutics)
Attend the CNSide Educational Symposium
We also invite conference attendees to join our educational symposium focused on the evolving role of advanced CSF diagnostics in leptomeningeal metastases.
The symposium will feature expert perspectives on:
- Current challenges in diagnosing and monitoring leptomeningeal metastases
- Emerging clinical evidence supporting advanced CSF tumor cell analysis
- Real-world applications of CNSide in patient management
- Future directions for precision diagnostics in CNS cancers
This educational session is designed for physicians, researchers, advanced practice providers, and laboratory professionals seeking practical insights into the rapidly evolving landscape of LM care.
Space is limited, and advance registration is encouraged.
Reserve your symposium seat or request a recording of the symposium here:
https://docs.google.com/forms/d/e/1FAIpQLSeXDStwqCFKpSsC0smK0b0jov6E5WX5bg4lFo8CxKB8N9e7WQ/viewform
About CNSide® Diagnostics
CNSide® is a proprietary diagnostic platform designed to detect and characterize tumor cells in cerebrospinal fluid (CSF) from patients with leptomeningeal metastases. The platform combines advanced technologies to support enhanced diagnostic insights and help address unmet needs in neuro-oncology.nsights and help address unmet needs in neuro-oncology.
0 Comments